skip to Main Content

Targeting Mitochondrial Metabolism Shows Promise in Pancreatic Cancer

Newsfeed image, light gray text on dark gray background
Researchers report promising results from a phase I trial evaluating CPI-613, which targets mitochondrial metabolism, in combination with modified FOLFIRINOX chemotherapy for the treatment of metastatic pancreatic cancer.

They say: “This study provides encouraging evidence for a novel, potentially effective combination chemotherapy regimen […] that was safe and well tolerated in patients with metastatic pancreatic cancer.” Read more . . .

Back To Top